Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Cell & Gene Therapy
Biotech
Oncternal stock sinks 60% amid layoffs, trial terminations
Oncternal is folding all clinical trials and laying off staff, turning its energy toward exploring alternatives such as asset sales or an acquisition.
Gabrielle Masson
Sep 12, 2024 10:51am
AAV gene therapy biotech unveils with 10 pipeline products
Sep 12, 2024 7:00am
BridgeBio cuts gene therapy budget as clinical data disappoint
Sep 11, 2024 7:50am
Carisma, Moderna expand cell therapy collab to autoimmune area
Sep 10, 2024 12:31pm
Fibroblast cell therapy toughens skin in small clinical trial
Sep 9, 2024 2:26pm
Medera plans SPAC merger to advance cardiac gene therapies
Sep 5, 2024 10:50am
More News
Novartis ignites new stage of Voyager pact with $15M capsid deal
Sep 5, 2024 9:45am
ArsenalBio raises $325M, pivots away from former lead asset
Sep 4, 2024 8:00am
Acepodia, Pfizer click together for chemistry-based cell therapy
Sep 3, 2024 5:00pm
French CRO adopts Medidata's platform to consolidate data
Sep 3, 2024 12:55pm
See more stories
